Email this article Chronic constipation in the practice of a therapist: Features of therapy for comorbidity
- Authors: Svistunov AA1, Osadchuk MA1, Butorova LI1, Tokmulina GM1
-
Affiliations:
- ФГБОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России
- Issue: Vol 89, No 4 (2017)
- Pages: 69-74
- Section: Editorial
- URL: https://journal-vniispk.ru/0040-3660/article/view/32219
- DOI: https://doi.org/10.17116/terarkh201789469-74
- ID: 32219
Cite item
Full Text
Abstract
Aim. To evaluate the clinical efficacy of laxatives with different pharmacological effects in the combination therapy in patients with chronic constipation (CC) concurrent with obesity, hypertensive disease, and type 2 diabetes mellitus (DM). Subjects and methods. A total of 110 people (45 men, 65 women) aged 45 to 72 years with CC in the presence of concomitant diseases: grade 1 or 2 hypertensive disease + obesity + type 2 DM. The investigators determined the severity of abdominal pain syndrome and flatulence, by indicating the mean frequency of defecations per week and fecal consistency according to the Bristol stool scale; anthropometric parameters; serum biochemistry tests; and serum lipoprotein phenotyping. Quality of life was assessed by the SF-36 questionnaire. The patients were divided into 3 groups according their use of agents: 1) dietary fiber (psyllium); 2) osmotic laxatives (disaccharides); 3) osmotic laxatives (polyethylene glycol). Results. The patients taking psyllium to treat constipation showed an increasing frequency of defecations and normalization of stool consistency. Incorporating psyllium into combination therapy was accompanied by a significant decrease in the levels of total cholesterol and low-density lipoprotein cholesterol. A similar trend was observed for serum triglycerides. The patients receiving combination therapy including other laxatives displayed no significant differences between lipid metabolic parameters at the beginning and after the end of treatment. Conclusion. The whole complex of properties of psyllium (Mucofalk) can be fully realized in patients with comorbidity and chronic constipation, which is accompanied not only by the normalization of bowel emptying, but also by marked positive changes in the main lipid metabolic parameters and by a reduction in overweight.
Full Text
##article.viewOnOriginalSite##About the authors
A A Svistunov
ФГБОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава РоссииМосква, Россия
M A Osadchuk
ФГБОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава РоссииМосква, Россия
L I Butorova
ФГБОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава РоссииМосква, Россия
G M Tokmulina
ФГБОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава РоссииМосква, Россия
References
- Fortin M, Bravo G, Hudon C, Vanasse A, Lapointe L. Prevalence of multimorbidity among adults seen in family practice. Ann Fam Med. 2005;3:223-228 doi: 10.1370/afm.272
- Калинин А.В, Буторова Л.И. Особенности диагностики и лечения запоров у лиц пожилого возраста. РЖГГК. 2010;20;4;58-67.
- Сhoung RS, Locke GR, Schleck CD, Zinsmeister AR, Talley NJ. Cummulative incidence of chronic constipations: A population based study 1988—2003. Aliment Pharm Ther. 2007;26;1521-1528. doi: 10.1111/j.1365-2036.2007.03540.x
- Nyrop KA, Palsson OS, Levy RL, Von Koff M, Feld AD, Turner MJ, Whitehead WE. Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhea and functional abdominal pain. Aliment Pharmacol Ther. 2007;26:237-248. doi: 10.1111/j.1365-2036.2007.03370.x
- Sileri P, Franceschilli L, Cadeddu F, De Luca E, D’Ugo S, Tognoni V, Camperchioli I, Benavoli D, Di Lorenzo N, Gaspari AL, Gentileschi P. Prevalence of defaecatory disorders in morbidly obesepatients before and after bariatric surgery. Gastrointest Surg. 2012;16:62-66;discussion. doi: 10.1007/s11605-011-1705-5
- Phatak UP, Pashankar DS. Prevalence of functional gastrointestinal disordersin obese and overweight children. Int J Obes (Lond). 2014;38(iss.10):1324-1327. doi: 10.1038/ijo.2014.67
- Маевская Е.А., Кучерявый Ю.А., Маев И.В. Неалкогольная жировая болезнь печени и хронический запор: случайная или очевидная ассоциация в практике гастроэнтеролога? Клинические перспективы гастроэнтерологии, гепатологии. 2015;1:27-36.
- Salmoirago-Blotcher E, Crawford S, Jackson E, Ockene J, Ockene I. Constipation and Risk of Cardiovascular Disease among Post-Menopausal Women. Am J Med. 2011;124(8):714-723. doi: 10.1016/j.amjmed.2011.03.026
- Salmoirago-Blotcher E, Crawford SL, Jackson EA, Ockene JK, Ockene IS. Constipation and Risk of Cardiovascular Events in Menopausal Women. Circulation. 2009;120:S408.
- Seki E, Schnabl B. Role of innateimmunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol. 2012;590:447-458. doi:jphysiol.2011.219691
- Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:1712-1723. doi: 10.3748/WJG.v20.i7.1712
- Свистунов А.А., Осадчук М.М., Бурдина. В.О. Синдром раздраженного кишечника как проблема первичного звена здравоохранения. Врач. 2014;3:14-18.
- Авдеев В.Г. Диабетическая энтеропатия. Фарматека. 2010; 3:46-49.
- Pare P. The approach to diagnosis and treatment of chronic constipation: suggestions for a general practitioner. Can Gastroenterol. 2011;25(Suppl.B):36B-40B. doi: 10.1155/2011/368189
- Клинические рекомендации Российской гастроэнтерологической ассоциации по лечению взрослых пациентов с хроническим запором, 2014
- Giacosa A, Rondanelli M. The right fiber for the right disease: an update on the psyllium seed husk and the metabolic syndrome. J Clin Gastroenterol. 2010;44:S58-S60. doi: 10.1097/mcg.0b013e3181e123e7
- Ардатская М.Д. Клиническое применение пищевых волокон: Методическое пособие. М.: 4 ТЕ Арт; 2010.
Supplementary files
